Barinthus Biotherapeutics plc (ADR)
General ticker "BRNS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $37.3M (TTM average)
Barinthus Biotherapeutics plc (ADR) does not follow the US Stock Market performance with the rate: -23.8%.
Estimated limits based on current volatility of 4.4%: low 0.61$, high 0.67$
Factors to consider:
- Total employees count: 14 (-86.7%) as of 2025
- Top business risk factors: Inability to raise capital, Failure to obtain approval, Lack of sales capabilities, Third-party risks, Market competition
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.49$, 1.44$]
- 2026-12-31 to 2027-12-31 estimated range: [0.54$, 1.53$]
Financial Metrics affecting the BRNS estimates:
- Positive: with PPE of -0.4 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 1.45 > -0.60
- Positive: Inventory ratio change, % of -89.60 <= -0.75
- Positive: Shareholder equity ratio, % of 75.59 > 64.23
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0.18 <= 0.74
Short-term BRNS quotes
Long-term BRNS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.80MM | $14.97MM | $0.00MM |
| Operating Expenses | $84.72MM | $82.94MM | $70.56MM |
| Operating Income | $-83.91MM | $-67.97MM | $-70.56MM |
| Non-Operating Income | $7.39MM | $6.74MM | $3.92MM |
| Interest Expense | $0.03MM | $0.05MM | $0.05MM |
| R&D Expense | $44.87MM | $38.25MM | $25.56MM |
| Income(Loss) | $-76.52MM | $-61.23MM | $-66.63MM |
| Taxes | $-3.08MM | $-0.04MM | $-0.17MM |
| Net Income(Loss)* | $-73.35MM | $-61.07MM | $-66.43MM |
| Stockholders Equity | $186.78MM | $130.03MM | $74.21MM |
| Assets | $214.51MM | $160.33MM | $98.17MM |
| Operating Cash Flow | $-50.92MM | $-28.94MM | $-47.98MM |
| Capital expenditure | $5.41MM | $0.89MM | $0.04MM |
| Investing Cash Flow | $-5.41MM | $-0.89MM | $0.42MM |
| Financing Cash Flow | $1.87MM | $2.16MM | $0.00MM |
| Earnings Per Share** | $-1.91 | $-1.55 | $-1.64 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.